News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Verona Pharma Release: Further Clinical Data Highlighting the Significant Bronchodilator Activity of Novel Dual PDE3/4 Inhibitor RPL554 Presented at American Thoracic Society International Conference


5/21/2013 10:04:33 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

21 May 2013 -- Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, today announces that a further poster was presented on Tuesday 21 May as part of the scientific programme at American Thoracic Society (ATS) International Conference, Philadelphia, USA, 17- 22 May 2013. The abstract for this poster is reproduced below.

[Poster Board # 315] RPL554, A Dual PDE3/4 Inhibitor, Is Well Tolerated And Maintains Bronchodilator Activity When Administered By Inhalation To Mild-To-Moderate Allergic Asthmatics On 6 Consecutive Days, [Publication Page: A3875]

L. Franciosi, PhD1, R. Zuiker, MD, MBA2, I.M. Kamerling, MD2, J. Burgraaf, MD, PhD2, A. Cohen, MD, PhD2, M. Walker, PhD1, C. Page, PhD1 1London/UK, 2Leiden/NL

Rationale: RPL554, an inhaled dual phosphodiesterase 3/4 inhibitor, has bronchodilator, bronchoprotective and anti-inflammatory properties in pre-clinical models of allergen-induced asthma. Single doses of nebulized RPL554 in healthy subjects and allergic asthmatics were well tolerated and induced substantial bronchodilation and bronchoprotection in the asthmatics. The present study assessed tolerability and consistency of bronchodilator responses to inhaled RPL554 given on 6 consecutive days.

Methods: In a single-blind randomised placebo study, 12 clinically stable mild-to-moderate allergic asthmatics males (age: 19-52 years; BMI: 20-27 kg/m2; FEV1: 2.9-5.1 Litres; FEV1: 75-104% pred. FVC: 4.2-7.0 Litres; FEV1/FVC: 56-90%; PEF: 7.1-13 Litres; PC20Mch: 0.10-6.1 mg/mL) not requiring controller nor regular bronchodilator therapy were studied. The tolerability and bronchodilator effects of inhaled RPL554 given daily at 0.018 mg/kg for 6 days was investigated using standard safety measures (i.e., heart rate, blood pressure and ECG), pharmacokinetics (i.e., Cmax, AUC, T1/2), and spirometry (i.e., FEV1, PEF) on days 1, 3 and 6 at the same time and compared to placebo measured at day -1 only. Study medication was administered over a 10 minute period by a calibrated electronic nebuliser and oro-nasal mask.

Results: The 6 days of treatment were well-tolerated with a few mild and short lasting minor adverse events reported. The most frequent were headache, irritation of the larynx and dryness of the throat. Heart rate and blood pressure did not change consistently with minor changes in heart rate and diastolic blood pressures at day 6. RPL554 drug retained its effect on FEV1 and PEF over the whole treatment period. The maintained effectiveness of RPL554 was shown by the maximum increases in FEV1, as compared with day-1 responses, were which were 555, 505 and 485 mL, respectively for days 1, 3 and 6. The only statistical difference was between days 1 and 6 (p=0.031 by Least Squares Mean), but the overall pattern was for a clearly maintained effect. The PEF values remained comparable over study days 1, 3 and 6. Pharmacokinetic evaluation of concentrations of RPL554 in plasma showed limited, non-consistent changes in terms of Cmax, AUC, T1/2, indicating no major changes in systemic accumulation or metabolism. Conclusions: In mild-to-moderate allergic asthmatics, daily doses of nebulised RPL554 for 6 consecutive days were well-tolerated and produced consistent bronchodilation without any accumulation or altered systemic metabolism.

Am J Respir Crit Care Med 187;2013:A3875

For further information please contact:

Verona Pharma plc Tel: 020 7863 3300

Clive Page, Chairman

Jan-Anders Karlsson, CEO

WH Ireland Limited Tel: 020 7220 1666

Chris Fielding

Nick Field

FTI Consulting Tel: 020 7831 3113

Julia Phillips

Simon Conway

About Verona Pharma plc

Verona Pharma is developing first-in-class drugs to treat respiratory disease, such as COPD, asthma and chronic, severe cough. The Company has three drug programmes, two of which are in Phase II. The lead programme, RPL554, is an innovative dual phosphodiesterase (PDE) 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties. VRP700 is an innovative product for suppressing chronic, severe cough in patients with underlying lung disease. In its third programme, Verona Pharma is investigating novel anti-inflammatory molecules, called NAIPs, for a wide range of respiratory and inflammatory diseases.

About RPL554 for the treatment of COPD and Asthma

Verona’s lead drug, RPL554, is a dual phosphodiesterase (PDE) 3 and 4 inhibitor being developed as a novel treatment for chronic obstructive airways disease such as COPD and asthma with bronchodilator and anti-inflammatory effects. Both effects are essential to improve symptoms in patients with COPD or asthma. RPL554 is currently in phase II for both diseases.

COPD is a chronic lung disease with significant unmet need for which current treatment is far from optimal, as it often has unwanted side-effects and/or limited effectiveness. COPD is most commonly characterised by fixed airflow obstruction and chronic airways inflammation resulting from exposure to irritants like tobacco smoke. Asthma, which remains one of the most common chronic diseases in the world, is characterised by recurrent breathing problems and symptoms such as breathlessness, wheezing, chest tightness, and coughing. The market for COPD and asthma drugs is estimated to be £20 billion [source: visiongain].

About VRP700 for the treatment of Cough

VRP700 is Verona Pharma's lead drug compound for the treatment of cough, having a novel mechanism of action involving the suppression of cough initiating signals originating from cough sensory nerve endings located in the lungs. A clinical trial completed at the University of Florence, Italy in September 2011 clearly demonstrated significant anti-tussive effects with nebulised VRP700 in hospitalized patients with chronic severe cough.

Cough can be a very debilitating comorbidity reported by patients, especially those with respiratory conditions such as asthma, COPD, lung cancer, interstitial lung disease, fibrosis or lung infections. It is a neglected symptom which is often self-medicated. Consumer spending on OTC medications, including those for cough, grew by 10% over 2005-10, to reach GBP532 million [source: Mintel]. However, there is very little clinical evidence for such OTC cough medications being really effective and it is widely recognised by the medical community that there is a large need for more effective drugs to control and prevent pathologically induced coughing.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES